Agomab Spain S.L.

Quick facts

Phase 2 pipeline

• AGMB-129 · Oncology
  AGMB-129 is an anti-CD47 monoclonal antibody.

Phase 1 pipeline

• AGMB-447

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Agomab Spain S.L. portfolio CI brief
• Agomab Spain S.L. pipeline updates RSS